2-(喹啉-6-基)丙酸 | 959585-30-9

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-(喹啉-6-基)丙酸
• 英文名称: 2-(quinolin-6-yl)propanoic Acid
• 英文别名: 2-quinolin-6-yl-propionic acid；2-quinolin-6-ylpropionic acid；2-quinolin-6-ylpropanoic acid
• CAS: 959585-30-9
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: PZEAPGRLLGDEEL-UHFFFAOYSA-N

物化性质

• 沸点：
  380.3±17.0 °C(Predicted)
• 密度：
  1.246

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090
• 储存条件：
  存储条件：密封、干燥、避光，温度范围为2-8°C。

反应信息

• 作为反应物：
  描述：

  2-(喹啉-6-基)丙酸 在 三乙胺 、 氯甲酸乙酯 、 sodium azide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 17.17h， 生成 2-(quinolin-6-yl)propanoyl azide
  参考文献：
  名称：

  [EN] UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS
  [FR] COMPOSÉS D'URÉE ACYCLIQUES SERVANT DE MODULATEURS DE LA GAMMA-SÉCRÉTASE

  摘要：

  本发明提供了化合物Formula (I)，它们是γ-分泌酶调节剂，因此可用于治疗通过调节γ-分泌酶可治疗的疾病，如阿尔茨海默病。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。

  公开号：

  WO2009137404A1
• 作为产物：
  描述：

  喹啉-6-乙酸甲酯 在 lithium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 4.5h， 生成 2-(喹啉-6-基)丙酸
  参考文献：
  名称：

  Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats

  摘要：

  The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S)-6-(1-(6-(1-methyl-1H-pyrazol -4-yl) - [1,2,4] triazolo [4,3-b pyridazin- 3-yl) ethyl) quinoline (8) was discovered from a highly selective high-throughput screening hit. via structure-based drug design and medicinal chemistry lead optimization. Compound 8 had many attractive properties meriting preclinical evaluation. Broad off-target screens identified 8 as a pan-phosphodiesterase (PDE) family inhibitor, which was implicated in a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in in vivo safety evaluations in rats. Compound 8 was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. The learning from multiparameter lead optimization and strategies to avoid the toxicity attrition at the late stage of drug discovery are discussed.

  DOI：

  10.1021/jm400926x

文献信息

• Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions
  申请人：FRANK Robert

  公开号：US20090156590A1

  公开（公告）日：2009-06-18

  Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

  与公式I相对应的辣椒素受体配体化合物：含有这种化合物的药物组合物，生产这种化合物的方法，以及使用这种化合物治疗或抑制疼痛和各种其他疾病或症状的方法。
• [EN] AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE<br/>[FR] INHIBITEURS À BASE DE TRIAZOLOPYRAZOLE, TRIAZOLOTHIADIAZOLE DE LA PROTÉINE KINASE C-MET
  申请人：VERTEX PHARMA

  公开号：WO2010138665A1

  公开（公告）日：2010-12-02

  The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula (I) and methods of using the compositions in the treatment of proliferative disorders.

  本发明涉及公式（I）的化合物，该化合物在抑制c-Met蛋白激酶方面具有用途。该发明还提供了包含公式（I）化合物的药学上可接受的组合物，并提供了使用这些组合物治疗增生性疾病的方法。
• [EN] SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE<br/>[FR] INHIBITEURS À BASE DE PYRAZOLE SUBSTITUÉ DE LA PROTÉINE KINASE C-MET
  申请人：VERTEX PHARMA

  公开号：WO2010138663A1

  公开（公告）日：2010-12-02

  The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula (I) and methods of using the compositions in the treatment of proliferative disorders.

  本发明涉及式(I)的化合物，可用于抑制c-Met蛋白激酶。该发明还提供了包含式(I)化合物的药学上可接受的组合物，以及使用这些组合物治疗增生性疾病的方法。
• [EN] INHIBITORS OF C-MET PROTEIN KINASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C-MET
  申请人：VERTEX PHARMA

  公开号：WO2010138673A1

  公开（公告）日：2010-12-02

  The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.

  本发明涉及式(I)的化合物，该化合物在抑制c-Met蛋白激酶方面具有用途。该发明还提供了包含式I化合物的药学上可接受的组合物，并提供了使用这些组合物治疗增殖性疾病的方法。
• [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE
  申请人：He Feng

  公开号：US20130324526A1

  公开（公告）日：2013-12-05

  The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  该发明涉及公式（I）的化合物及其盐：其中取代基如规范中定义；公式（I）的化合物用于治疗人体或动物体，特别是涉及c-Met酪氨酸激酶介导的疾病或病况；公式（I）的化合物用于制造用于治疗此类疾病的药物；包含公式（I）的化合物的药物组合物，可选地与联合伙伴一起，并且公式（I）的化合物的制备方法。